N-Methyl-D-aspartate (
NMDA)/
glycine site antagonists were tested for their ability to prevent
cocaine-induced convulsions and lethality in Swiss Webster mice. Pre-treatment of mice with the novel
NMDA/
glycine site antagonists
ACEA-1021 (5-nitro-6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione) or
ACEA-1328 (5-nitro-6,7-dimethyl-1,4-dihydro-2,3-quinoxalinedione) attenuated
cocaine-induced convulsions; these effects were pharmacologically antagonized with D-
cycloserine. The structurally-related
NMDA/
glycine site antagonist
DCQX (6,7-dichloroquinoxaline-2,3-dione) and the structurally-unrelated
NMDA/
glycine site partial agonist
HA-966 (3-amino-1-hydroxy-2-pyrrolidinone) also attenuated
cocaine-induced convulsions, with the R(+)-isomer of
HA-966 being more effective than the S(-)-isomer. In contrast, the selective alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic
acid (
AMPA) receptor antagonist,
NBQX (1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-
benzo[f]quinoxaline-7-
sulfonamide) , failed to provide statistically significant protection although it shares the 2,3-quinoxalinedione structure of
DCQX and the ACEA compounds. Pre-treatment with
ACEA-1021,
ACEA-1328,
DCQX, or R(+)-
HA-966 also attenuated
cocaine-induced lethality in mice. Significantly, post-treatment with
ACEA-1021, immediately prior to or after the onset of
seizures, prevented death in up to 86% of mice receiving a lethal dose of
cocaine; post-treatment with vehicle resulted in death of all mice. The results suggest the utility of targeting excitatory mechanisms for the treatment of
cocaine overdose and offer a novel base structure from which effective
pharmacotherapies can be developed.